Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2006-07-05
2011-11-29
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S130100
Reexamination Certificate
active
08066996
ABSTRACT:
Antibodies, or antigen-binding fragment thereof, which bind to a CCR7 receptor are capable of selectively killing, impairing migration and/or blocking dissemination of tumor cells expressing a CCR7 receptor. Use of said antibodies for killing or for inducing apoptosis of said tumor is disclosed, thus providing an alternative therapy for treatment of cancer which tumor cells express a CCR7 receptor.
REFERENCES:
patent: 2004/0185507 (2004-09-01), Giles-Komar et al.
patent: 1 255 112 (2002-11-01), None
patent: 2004104574 (2004-12-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Alfonso-Perez, Manuel, et al., “Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia”, “Journal of Leukocyte Biology”, Jun. 2006, pp. 1157-1165, vol. 79, No. 6.
Corcione, Anna, et al., “CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells”, “Clinical Cancer Research”, Feb. 1, 2004, pp. 964-971, vol. 10, No. 3.
Ghobrial, Irene M., et al., “Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia . . . ”, “May Clinic Proceedings”, Mar. 2004, pp. 318-325, vol. 79, No. 3.
Lopez-Giral, Sonia, et al., “Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic . . . ”, “Journal of Leukocyte Biology”, Aug. 2004, pp. 462-471, vol. 76, No. 2.
Till, Kathleen J., et al., “The chemokine receptor CCR7 and alpha-4 integrin are important for migration of chronic lymphocytic leukemia cells . . . ”, “Blood”, Apr. 15, 2002, pp. 2977-2984, vol. 99, No. 8.
Cignetti, Alessandro, et al., “Chemokine receptor expression in acute myeloid leukemia cells (Abstract)”, “Blood”, Nov. 16, 2000, p. 116a, vol. 11, No. 1.
Calleja Cecilia Munoz
Giral Sonia Lopez
Perez Manuel Jesus Alfonso
Huff Sheela J
Hulquist Steven J.
Hulquist IP
Reynolds Kelly K.
Universidad Autonoma de Madrid
LandOfFree
Anti-CCR7 receptor antibodies for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CCR7 receptor antibodies for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CCR7 receptor antibodies for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293202